SEER · Seer, Inc.

On April 27, 2026, Seer, Inc. announced that its Board of Directors had unanimously rejected a revised unsolicited, non-binding proposal from the Radoff-JEC Group (Bradley L. Radoff, Michael Torok, and affiliates) received on April 24, 2026. The proposal sought to acquire all outstanding shares of Seer’s Class A common stock for $2.35 per share in cash plus a contingent value right. Following a thorough review with independent financial and legal advisors, the Board concluded that the Revised Proposal significantly undervalues Seer and is not in the best interests of stockholders. Specifically, the Board highlighted that the implied equity value is materially below the sum of the Company's current cash, cash equivalents, and investments, failing to account for the value of Seer’s platform, technology leadership, and growth prospects. Dr. Nicolas Roelofs, Lead Independent Director, emphasized the Company's compelling growth potential and differentiated platform in the deep, unbiased proteomics market. The Board is also actively overseeing the Company's strategy and will review proposed director nominees submitted by the Radoff-JEC Group for the upcoming 2026 Annual Meeting. Perella Weinberg Partners LP and Wilson Sonsini Goodrich & Rosati are advising the Company.